Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of PF-08634404 plus chemotherapy in previously untreated transformed small cell lung cancer
jRCT2031260080Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of PF-08634404 in small cell lung cancer (SCLC), sponsored by Pfizer. Primary endpoints: Confirmed objective response rate and Number of participants with adverse events. Started Apr 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031260080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260080.